Increasing prevalence of obesity coupled with rising adoption of sedentary lifestyle is the major factor influencing Non-alcoholic Steatohepatitis (NASH) market growth.

New York, NY -- (SBWire) -- 03/30/2019 --The global Non-alcoholic Steatohepatitis (NASH) market is expected to reach USD 13.38 Billion by 2026, according to a new report by Reports and Data. This can be mainly associated with increasing consumption of fats globally. Based on statistics, Nonalcoholic Fatty Liver Disease (NAFFLD) affects around 80 million to 100 million Americans. NAFLD is expected to become the most common chronic liver condition globally in relation to the obesity and type 2 diabetes in the coming years. Estimates suggest that the incidence of NASH is projected to witness an increase of around 63% between 2015 and 2030.

Increase in the number of expected launch of pipeline drugs is also a significant factor stimulating market demand. The current statistics for the U.S. suggest that the healthcare cost associated with NASH is around USD 5 billion. Since the incidence of NASH is projected to rise significantly, estimates suggest that, if unchecked, the healthcare costs associated with NASH could rise up to USD 18 billion by 2030. Companies around the world have been focusing on bringing out new drugs in the market for the treatment of the disease.

Request for premium sample copy of Non-Alcoholic Steatohepatitis (NASH) report in PDF format to understand the structure of complete report @ https://www.reportsanddata.com/sample-enquiry-form/1111

The major players covered in this Non-Alcoholic Steatohepatitis (NASH) report are
Genfit, Intercept Pharmaceuticals, Gilead Sciences, Galmed Pharmaceuticals, Inventiva, Allergan and Tobira Therapeutics

Elafibranor is projected to be one of the fastest growing drugs of the NASH market. The segment is projected to grow at a CAGR of 55.4% in the forecast period. The drug which is an oral treatment is GENFIT's lead pipeline product. It has been positioned as a first-in-class drug to treat NASH. The drug is currently being evaluated in the clinical Phase 3 study RESOLVE-IT.

North American market is forecasted to grow at a CAGR of 53% in the coming years. The disease is considered to be one of the leading causes of cirrhosis in adults in the U.S. High incidence of diabetes and obesity in the region are considered to be the main reason behind increasing incidence of NASH. Based on American Liver Foundation's National Medical Advisory Committee currently around 30 million Americans have been diagnosed with NASH. Additionally, around 90% of the NASH patients suffer from either obesity or diabetes.How geography and sales fit together

The study works as a boon for all business owners trying to identify the exact size of the target audience in a specific geographic location.

Non-Alcoholic Steatohepatitis (NASH) enables entrepreneurs to determine the regional market for their business expansion. The study answers the questions below:
- Where do the requirements come from?
- Where do non-potential customers reside?
- What is the buying behaviour of the customers dwelling in a particular area?
- What is the spending power of the customers in a specific region?

Our trend analysts look for the crucial connection between consumer trends, behaviour and values, to provide context for the sectors, demographics and global themes that matter to you.

Non-Alcoholic Steatohepatitis (NASH) Market split by Disease Cause, can be divided into:
- Hypertension
- Heart Disease
- High Blood Lipid
- Type 2 Diabetes
- Obesity

Non-Alcoholic Steatohepatitis (NASH) Market split by Drug Type, can be divided into:
- Vitamin E & Pioglitazone
- Ocaliva
- Elafibranor
- Selonsertib
- Cenicriviroc
- Others

Non-Alcoholic Steatohepatitis (NASH) Market split by End-user, can be divided into:
- Hospitals
- Clinics
- Homecare settings

Geographically, this Non-Alcoholic Steatohepatitis (NASH) report studies the key regions, focuses on product sales, value, market share and growth opportunity in these regions, covering:
- United States
- Europe
- China
- Japan
- Southeast Asia
- India

We can also provide the customized separate regional or country-level reports, for the following regions:
North America, United States, Canada, Mexico, Asia-Pacific, China, India, Japan, South Korea, Australia, Indonesia, Singapore, Rest of Asia-Pacific, Europe, Germany, France, UK, Italy, Spain, Russia, Rest of Europe, Central & South America, Brazil, Argentina, Rest of South America, Middle East & Africa, Saudi Arabia, Turkey, Rest of Middle East & Africa

Order Now (Customized report delivered as per your specific requirement)@ https://www.reportsanddata.com/checkout-form/1111

The study objectives of this Non-Alcoholic Steatohepatitis (NASH) report are:
# To analyze and study the global Non-Alcoholic Steatohepatitis (NASH) sales, value, status (2018-2026) and forecast (2018-2026);
# To analyze the top players in North America, Europe, China, Japan, Southeast Asia and India, # to study the sales, value and market share of top players in these regions.
#Focuses on the key Non-Alcoholic Steatohepatitis (NASH) players, to study the sales, value, market share and development plans in future.
#Focuses on the global key manufacturers, to define, describe and analyze the market competition landscape, SWOT analysis.
#To define, describe and forecast the market by type, application and region.
#To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
#To identify significant trends and factors driving or inhibiting the market growth.
#To analyze the opportunities in the market for stakeholders by identifying the high growth segments.
# To strategically analyze each submarket with respect to individual growth trend and their contribution to the market
# To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
# To strategically profile the key players and comprehensively analyze their growth strategies.

Browse complete Non-Alcoholic Steatohepatitis (NASH) report description @ https://www.reportsanddata.com/report-detail/non-alcoholic-steatohepatitis-nash-market

Key elements from table of content:

Chapter 10. Company Profiles
10.1. Genfit
10.1.1. Company Overview
10.1.2. Financial Performance
10.1.3. Product Insights
10.1.4. Strategic Initiatives
10.2. Intercept Pharmaceuticals
10.2.1. Company Overview
10.2.2. Financial Performance
10.2.3. Product Insights
10.2.4. Strategic Initiatives
10.3. Gilead Sciences
10.3.1. Company Overview
10.3.2. Financial Performance
10.3.3. Product Insights
10.3.4. Strategic Initiatives
Continued….

About Us:
Reports and Data Is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client's make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market.

Contact Us:
John Watson
Head of Business Development
Reports and Data | Web: https://www.reportsanddata.com/
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
News: www.reportsanddata.com/market-news